Applied Genetic Technologies Corporation

NasdaqGM:AGTC Lagerbericht

Marktkapitalisierung: US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Genetic Technologies Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Sue Washer

Geschäftsführender

US$1.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts37.4%
Amtszeit als Geschäftsführer20.7yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements1.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder11.3yrs

Jüngste Management Updates

Recent updates

AGTC receives positive feedback from FDA for manufacturing facility

Jul 26

Applied Genetic Technologies proposes stock offering to fund clinical trials

Jul 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

Jan 12

An Assessment Of Applied Genetic Technologies Corporation

Dec 14

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Jul 15

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

May 21
Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Applied Genetic trades lower after announcing the departure of chief scientific officer

Apr 26

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Feb 05
What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Jan 06
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Dec 11
What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic

Nov 11

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sue Washer im Vergleich zu den Einnahmen von Applied Genetic Technologies verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2022n/an/a

-US$70m

Jun 30 2022US$1mUS$551k

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

Vergütung im Vergleich zum Markt: Sue's total compensation ($USD1.47M) is above average for companies of similar size in the US market ($USD749.50K).

Entschädigung vs. Einkommen: Sue's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Sue Washer (61 yo)

20.7yrs

Amtszeit

US$1,473,567

Vergütung

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Susan Washer
President20.7yrsUS$1.47m0.21%
$ 26.7k
Jonathan Lieber
Chief Financial Officer1.2yrsUS$1.00mkeine Daten
Susan Schneider
Chief Medical Officerless than a yearUS$832.63kkeine Daten
Nicholas Muzyczka
Co-Founder23.8yrskeine Datenkeine Daten
Barry Byrne
Co-Founder23.8yrskeine Datenkeine Daten
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datakeine Datenkeine Daten
Richard Samulski
Co-Founder23.8yrskeine Datenkeine Daten
Terence Flotte
Co-Founder23.8yrskeine Datenkeine Daten
Gerald Reynolds
Chief Accounting Officer1.4yrskeine Daten0.013%
$ 1.6k
Abraham Scaria
Chief Scientific Officerless than a yearkeine Datenkeine Daten
Hope D'Oyley-Gay
General Counselless than a yearkeine Datenkeine Daten
David Knop
Senior Vice President of Process & Assay Developmentless than a yearUS$141.25kkeine Daten

1.4yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: AGTC's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Susan Washer
President19yrsUS$1.47m0.21%
$ 26.7k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datakeine Datenkeine Daten
Edward Hurwitz
Independent Director10yrsUS$65.23k0.041%
$ 5.1k
Anne VanLent
Independent Director6.3yrsUS$79.23kkeine Daten
Scott Koenig
Independent Chairman of the Board20.6yrsUS$101.50k0.051%
$ 6.4k
David Birch
Member of Ophthalmology Scientific Advisory Boardno datakeine Datenkeine Daten
William Aliski
Independent Director4.2yrsUS$78.23k0.013%
$ 1.6k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno datakeine Datenkeine Daten
James Rosen
Independent Director12.7yrsUS$72.34k0.0015%
$ 186.7
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno datakeine Datenkeine Daten
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno datakeine Datenkeine Daten
Robert Molday
Member of Ophthalmology Scientific Advisory Boardno datakeine Datenkeine Daten

11.3yrs

Durchschnittliche Betriebszugehörigkeit

65.5yo

Durchschnittliches Alter

Erfahrener Vorstand: AGTC's board of directors are seasoned and experienced ( 11.3 years average tenure).